Sandra Horning, MD

Sandra Horning is an expert in the field of lymphoma therapy and has been at the forefront of biopharmaceutical innovation for many years. Sandra previously served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche from 2014 to 2019. During her time at Genentech/Roche, she oversaw the approval of 15 new medicines for multiple disease areas, including cancer and multiple sclerosis. Prior to joining Genentech, Sandra was a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation, at Stanford University for more than 20 years, where she remains an Emerita Professor. At Stanford, she specialized in the treatment of lymphomas, authoring more than 150 studies and participating in more than 50 clinical trials, including multiple studies involving MRD. She was President of the American Society of Clinical Oncology from 2005 to 2006 and served on the editorial boards of the Journal of Clinical Oncology, Clinical Cancer Research, Clinical Lymphoma, Leukemia & Lymphoma, the Annals of Internal Medicine, and The American Journal of Medicine. She received her MD from the University of Iowa School of Medicine and completed her postgraduate fellowship in oncology and cancer biology at Stanford University.